How Do You Rank With the Latest Advances in EGPA Diagnosis and Management?
Webinar/Online
Wednesday, December 3, 2025 at 6:00pm ET - 7:00pm ET
Add this event to your calendar
Info
Topic
Join us online for this interactive webinar where cutting-edge insights on eosinophilic granulomatosis with polyangiitis (EGPA) will be delivered through expert panels and real-time case discussions. Engage with experts to enhance your clinical practice and improve patient outcomes through the latest clinical evidence and guidelines for EGPA.
Credits Offered
This event offers
1.0 contact hour
to attendees.
Accreditation Info:
ANCC.
Additional Information
Goal Statement
The goal of this activity is to improve learners’ knowledge and competence in diagnosing and managing patients with EGPA.
Target Audience
This activity is intended for pulmonologists, allergists, rheumatologists, nurses, physician associates, and other healthcare professionals who manage patients with EGPA.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Detail key cellular and immunologic components of EGPA pathophysiology
-
Apply recommended approaches for diagnosis and classification of individuals with EGPA
-
Leverage recent clinical evidence and guidelines in treatment decisions for patients with EGPA
-
Incorporate patient preferences and goals through shared decision-making to design EGPA treatment strategies
Agenda
Pathophysiology Quiz and Best Practice in EGPA Diagnosis
Section 1: EGPA Pathophysiology
- Epidemiology of EGPA
- Brief overview of EGPA symptoms, phases
- Role of eosinophils and IL-5
- Genetic and environmental factors
Diagnosis and Classification
- ACR 1990 criteria for classification of Churg-Strauss syndrome
- 2022 ACR/EULAR
- Clinical trials enrollment criteria
- Phenotypic manifestations: ANCA positive vs ANCA negative
- Laboratory studies to further evaluate for EGPA
- Clinical case discussion
Section 2: Recent Advances in EGPA Treatment
Evidence-Based Management of Severe and Nonsevere EGPA
- Comparing guidelines
- Evidence for targeting IL-5 and IL-5Rs
- Role of immunosuppressive agents
- Systemic vs respiratory manifestations
- Clinical case discussion
Section 3: Partnering With Patients to Achieve and Maintain Remission in EGPA
Addressing the Burden of EGPA Through Shared Decision‑making
- Understanding the patient burden
- Shared decision-making in EGPA management
- Managing comorbidities
- Multidisciplinary care pathways
Q&A
Speakers
Professor of Medicine
Division of Pulmonary, Critical Care, Sleep Medicine & Physiology
University of California San Diego
La Jolla, California
Professor of Medicine
Director of the Vasculitis Center
Fellowship Program Director
Section of Rheumatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Professor of Medicine
Director, NJH Asthma Institute
National Jewish Health
Denver, Colorado